Prognostic significance of sequential 18F-FDG PET/CT during frontline treatment of peripheral T cell lymphomas
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The prognostic significance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET/CT) in peripheral T-cell lymphomas (PTCLs) are controversial. We explored the prognostic impact of sequential 18F-FDG PET/CT during frontline chemotherapy of patients with PTCLs. Methods: In total, 143 patients with newly diagnosed PTCLs were included. Sequential 18F-FDG PET/CTs were performed at the time of diagnosis, during chemotherapy, and at the end of chemotherapy. The baseline total metabolic tumor volume (TMTV) was calculated using the the standard uptake value with a threshold method of 2.5. Results: A baseline TMTV of 457.0 cm3 was used to categorize patients into high and low TMTV groups. Patients with a requirehigh TMTV had shorter progression-free survival (PFS) and overall survival (OS) than those with a low TMTV (PFS, 9.8 vs. 26.5 mo, p = 0.043; OS, 18.9 vs. 71.2 mo, p = 0.004). The interim 18F-FDG PET/CT response score was recorded as 1, 2–3, and 4–5 according to the Deauville criteria. The PFS and OS showed significant differences according to the interim 18F-FDG PET/CT response score (PFS, 120.7 vs. 34.1 vs. 5.1 mo, p < 0.001; OS, not reached vs. 61.1 mo vs. 12.1 mo, p < 0.001). Conclusions: The interim PET/CT response based on visual assessment predicts disease progression and survival outcome in PTCLs. A high baseline TMTV is associated with a poor response to anthracycline-based chemotherapy in PTCLs. However, TMTV was not an independent predictor for PFS in the multivariate analysis.
Abstract
Background/Aims: The prognostic significance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET/CT) in peripheral T-cell lymphomas (PTCLs) are controversial. We explored the prognostic impact of sequential 18F-FDG PET/CT during frontline chemotherapy of patients with PTCLs. Methods: In total, 143 patients with newly diagnosed PTCLs were included. Sequential 18F-FDG PET/CTs were performed at the time of diagnosis, during chemotherapy, and at the end of chemotherapy. The baseline total metabolic tumor volume (TMTV) was calculated using the the standard uptake value with a threshold method of 2.5. Results: A baseline TMTV of 457.0 cm3 was used to categorize patients into high and low TMTV groups. Patients with a requirehigh TMTV had shorter progression-free survival (PFS) and overall survival (OS) than those with a low TMTV (PFS, 9.8 vs. 26.5 mo, p = 0.043; OS, 18.9 vs. 71.2 mo, p = 0.004). The interim 18F-FDG PET/CT response score was recorded as 1, 2–3, and 4–5 according to the Deauville criteria. The PFS and OS showed significant differences according to the interim 18F-FDG PET/CT response score (PFS, 120.7 vs. 34.1 vs. 5.1 mo, p < 0.001; OS, not reached vs. 61.1 mo vs. 12.1 mo, p < 0.001). Conclusions: The interim PET/CT response based on visual assessment predicts disease progression and survival outcome in PTCLs. A high baseline TMTV is associated with a poor response to anthracycline-based chemotherapy in PTCLs. However, TMTV was not an independent predictor for PFS in the multivariate analysis.
참고문헌 (31)
- Gisselbrecht C, "Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte(GELA)", Blood, 92, pp.76~82 (1998)
- López-Guillermo A, "Peripheral T-cell lymphomas : initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R. E. A. L. Classification", Ann Oncol, 9, pp.849~855 (1998)
- Melnyk A, "Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560cases of aggressive non-Hodgkin’s lymphoma", Blood, 89, pp.4514~4520 (1997)
- Mamot C, "Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14(SAKK 38", 07), 2015, pp.33, 2523~2529
- Schöder H, "Prognostic value of interim FDG-PET in diffuse large cell lymphoma : results from the CALGB 50303 Clinical Trial", Blood, 135, pp.2224~2234 (2020)
- Aldin A, "Interim PET-results for prognosis in adults with Hodgkin lymphoma : a systematic review and meta-analysis of prognostic factor studies", Cochrane Database Syst Rev, 9, pp.CD012643~ (2019)
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Vercellino L, "High total metabolic tumor volume at baseline predicts survival independent of response to therapy", Blood, 135, pp.1396~1405 (2020)
- Mikhaeel NG, "Proposed new dynamic prognostic index for diffuse large B-cell lymphoma : international metabolic prognostic index", J Clin Oncol, 40, pp.2352~2360 (2022)
- Cottereau AS, "Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial", Blood, 131, pp.1456~1463 (2018)
- Casulo C, "18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma", Leuk Lymphoma, 54, pp.2163~2167 (2013)
- Cottereau AS, "Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients", J Nucl Med, 59, pp.589~595 (2018)
- El-Galaly TC, "Utility of interim and end-of-treatment PET", CT in peripheral T-cell lymphomas : a review of 124 patients, 2015, pp.90, 975~980
- International Non-Hodgkin’s Lymphoma Prognostic Factors Project, "A predictive model for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 329, pp.987~994 (1993)
- Gallamini A, "Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study", Blood, 103, pp.2474~2479 (2004)
- Zhang Y, "The role of pre-treatment and mid-treatment 18F-FDG PET", CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified(PTCL-NOS), 2021, pp.21, 145~
- Tutino F, "Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients : interobserver agreement and reproducibility across software platforms", Nucl Med Commun, 42, pp.284~291 (2021)
- Mettler J, "Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma", J Nucl Med, 60, pp.207~211 (2018)
- Hong R, "Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning", Int J Radiat Oncol Biol Phys, 67, pp.720~726 (2007)
- Zhu D, "Prognostic significance of metabolic parameters measured by(18)F-fluorodeoxyglucose positron emission tomography", computed tomography in patients with small cell lung cancer, 2011, pp.73, 332~337
- Wu X, "Early treatment response evaluation in patients with diffuse large B-cell lymphoma--a pilot study comparing volumetric MRI and PET", CT, 2011, pp.13, 785~792
- Barrington SF, "The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma", Lancet Haematol, 8, pp.e80~e93 (2021)
- Mehta-Shah N, "Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma", Blood Adv, 3, pp.187~197 (2019)
- Jiang C, "Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma(PTCL)", EJNMMI Res, 10, pp.110~ (2020)
- Cottereau AS, "Prognostic value of baseline total metabolic tumor volume(TMTV0)measured on FDG-PET", CT in patients with peripheral T-cell lymphoma(PTCL), 2016, pp.27, 719~724
- Gong H, "Prognostic value of baseline total metabolic tumour volume of 18F-FDG PET", CT imaging in patients with angioimmunoblastic T-cell lymphoma, 2021, pp.11, 64~
- Koh Y, "FDG PET for evaluation of bone marrow status in T-cell lymphoma", Clin Nucl Med, 44, pp.4~10 (2019)
- Pham AQ, "Accuracy of 18-F FDG PET", CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma-tissue remains the issue, 2017, pp.58, 2342~2348
- Zhou Y, "Prognostic values of baseline 18F-FDG PET", CT in patients with peripheral T-Cell lymphoma, 2020, pp.2020, 9746716~
- Schmitz C, "Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma : a subgroup analysis of the PETAL trial", Hematol Oncol, 38, pp.244~256 (2020)
- Ham JS, "The prognostic value of interim and end-of-treatment PET", CT in patients with newly diagnosed peripheral T-cell lymphoma, 2016, pp.6, e395~